Novartis to Invest US$23 Billion to State-of-the-Art Manufacturing and R&D Facility in USA
Introduction:
Novartis has announced plans to invest US$23 billion over the next five years to expand its manufacturing and R&D footprint across the United States.
Features:
The state-of-the-art facilities are designed to support end-to-end manufacturing and advanced R&D capabilities, incorporating cutting-edge technologies to optimise efficiency, scalability, and innovation across biologics and small molecule production.
Production capacity will include active pharmaceutical ingredients (APIs), biologics drug substances, secondary production, and packaging.
Four new manufacturing facilities will be built in yet-to-be-announced locations, including:
- Three sites dedicated to biologics drug substances, drug products, device assembly, and packaging.
- One site focused on chemical drug substances, oral solid dosage forms, and packaging.
Two radioligand therapy (RLT) manufacturing facilities will be built in Florida and Texas.
Three existing RLT facilities will be expanded in Indianapolis (IN), Millburn (NJ), and Carlsbad (CA).
A newly planned US$1.1 billion research hub in San Diego will offer world-class scientific infrastructure, expected to open between 2028 and 2029.
Specifications:
| Name | Novartis |
| Type | New Construction |
| Budget | US$23 billion |
| Year | 2029 |
